Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT819 in B-cell Malignancies
NCT04629729Phase 1Active, not recruiting
- Sponsor
- Fate Therapeutics
- Start
- Jul 2021
- Primary completion
- Jun 2025
- Modality
- CAR-T Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT819 in B cell lymphoma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-ALL) (12 arms), sponsored by Fate Therapeutics. Primary endpoints: Dose-Limiting Toxicities at Day 29 and Adverse Events at 15 years. Started Jul 2021; status: active, not recruiting.
02
Drugs
FT819
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04629729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629729.